Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.4K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tetrahedral DNA nano-PROTACs enable enhanced ocular penetration and efficient nucleolin degradation for choroidal neovascularization therapy.

Signal transduction and targeted therapy·2026
Same author

Synergistic Geometric and Interfacial Regulation of Silane-Modified Biomass Aerogels for Sustainable, Low-Resistance Particulate Filtration.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Supramolecular Modulation of Photoinduced Charge Transfer: Tuning Between Tunneling and Incoherent Hopping.

Angewandte Chemie (International ed. in English)·2026
Same author

Cryo-EM structure of human lipid phosphate phosphatase 2.

Structure (London, England : 1993)·2026
Same author

Platelet Factor 4: A Novel Therapeutic Inhibitor for Experimental Neovascular Age-Related Macular Degeneration.

Frontiers in bioscience (Landmark edition)·2026
Same author

Distinct types of regulated cell death in atherosclerosis.

Journal of pharmaceutical analysis·2026

Related Experiment Video

Updated: Feb 28, 2026

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.8K

Intraocular Triamcinolone Acetonide Injection Following Vitrectomy for Proliferative Diabetic Retinopathy: A

Hao Du1,2, Wei Zhang1,3, Han Han1

  • 1Tianjin Key Laboratory of Ocular Trauma, China-UK "Belt and Road" Ophthalmology Joint Laboratory, Department of Ophthalmology, Tianjin Medical University General Hospital, Ministry of Education International Joint Laboratory of Ocular Diseases, Tianjin Institute of Eye Health and Eye Diseases, Tianjin, China.

Current Eye Research
|February 27, 2026
PubMed
Summary

Combined vitrectomy and Triamcinolone acetonide (TA) injections significantly improve vision and reduce complications in proliferative diabetic retinopathy (PDR) patients. This treatment offers better visual outcomes and fewer postoperative issues compared to vitrectomy alone.

Keywords:
Triamcinolone acetonideproliferative diabetic retinopathytreatmentvitrectomy

More Related Videos

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

4.4K
Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy
11:03

Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy

Published on: January 22, 2018

10.6K

Related Experiment Videos

Last Updated: Feb 28, 2026

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.8K
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
11:20

Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases

Published on: June 14, 2021

4.4K
Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy
11:03

Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy

Published on: January 22, 2018

10.6K

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Surgical Innovation

Background:

  • Proliferative diabetic retinopathy (PDR) is a severe complication of diabetes, often leading to vision loss.
  • Vitrectomy is a standard surgical treatment for PDR, but recurrence and complications remain a challenge.

Purpose of the Study:

  • To evaluate the efficacy of combining vitrectomy with intravitreal Triamcinolone acetonide (TA) injections for PDR treatment.
  • To compare visual outcomes and complication rates between combined therapy and vitrectomy alone.

Main Methods:

  • A retrospective cohort study involving 133 patients (138 eyes) with PDR.
  • Patients were divided into a combined TA group (vitrectomy + TA injection) and a control group (vitrectomy alone).
  • Follow-up was conducted for 3 months, analyzing visual function recovery and PDR control.

Main Results:

  • The combined TA group showed significantly higher visual acuity improvement (86.67%) compared to the control group (71.43%).
  • Postoperative bleeding incidence was lower in the combined group (12.00%) versus the control group (23.81%).
  • Macular epiretinal membrane incidence was significantly reduced in the combined group (24.00%) compared to the control group (41.27%).

Conclusions:

  • Vitrectomy combined with intravitreal TA injection is effective in improving postoperative visual outcomes for PDR.
  • This combined approach may reduce the incidence of postoperative complications such as bleeding and epiretinal membrane formation.
  • The study suggests a potential benefit of TA in managing PDR post-vitrectomy.